Press release - No. 13/2017
Zealand Pharma: Invitation to Capital Market Day in New York on 25 January, and event in Copenhagen on 29 January
2018
- Zealand's management will provide an update on strategy and business
- Keynote presentations from two key opinion leaders
Copenhagen, Denmark, December 21, 2017 - Zealand announces that it will host a Capital Market Day for investors and analysts
in New York on Thursday 25 January 2018 at 12 to 3 pm, followed by an event in Copenhagen on Monday 29 January 2018, where external
speakers will not be present.
The Capital Market Days will include an update on the status of Zealand's business and its progress towards becoming a leader in
specialty gastrointestinal and metabolic diseases. Management will present the progress and outlook for glepaglutide for the
treatment of short bowel syndrome and dasiglucagon for diabetes care and treatment of congenital hyperinsulinsm (CHI) as well as an
update on the strong research pipeline.
In addition, we are proud to present two external speakers:
- David F. Mercer, M.D., Ph.D., associate professor in the UNMC Department of Surgery-Transplant and director of Nebraska
Medicine's Intestinal Rehabilitation Program, will provide important insights regarding the treatment of short bowel
syndrome.
- Jessica Castle, M.D. will provide a clinician perspective of glucagon. Jessica Castle is as an assistant professor at the
Harold Schnitzer Diabetes Health Center, Portland.
Capital Markets Event in Copenhagen
Date: |
Monday, 29 January 2018 |
Time: |
13:30 - 16:00 CET |
Venue: |
Zealand Pharma, Smedeland 36, 2600 Glostrup |
Webcast: |
This event will not be webcasted, but the presentations from the two key opinion leaders from the New York event will be
shown. |
Registration: |
Before January 26 2018 by mail jwr@zealandpharma.com
|
For further information, please contact:
Mats Blom, Executive Vice President, Chief Financial Officer
Tel.: +45 31 53 79 73, e-mail: mabl@zealandpharma.com
About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq Copenhagen and New York: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, design
and development of innovative peptide-based medicines. Zealand has a portfolio of medicines and product candidates under license
collaborations with Sanofi and Boehringer Ingelheim, and a pipeline of internal product candidates focusing on specialty
gastrointestinal and metabolic diseases.
Zealand is based in Copenhagen (Glostrup), Denmark. For further information about the Company's business and activities, please
visit www.zealandpharma.com or follow Zealand on LinkedIn or Twitter @ZealandPharma.
Attachments:
http://www.globenewswire.com/NewsRoom/AttachmentNg/6201d801-1afa-4c0f-8e08-ea82cbe9c8a5
![](http://www.globenewswire.com/newsroom/ti?ndecode=NzA2MzkjNzA1MTA3OA==)